Speakers

Nicholas Heimann

Chief Executive Officer

Nicholas Pharmaceuticals

Eric Halioua

Chief Executive Officer

PDC*line Pharma

Niranjan Sardesai

Chief Executive Officer

Geneos Therapeutics

Tom Davis

Chief Medical Officer

Genocea Biosciences

Victor Levitsky

Chief Scientific Officer

Targovax

Karin Jooss

Chief Scientific Officer

Gritstone Oncology

Hans-Peter Gerber

Chief Scientific Officer

3T Biosciences

Jessica Flechtner

Chief Scientific Officer

Genocea Biosciences

Laurent Humeau

Chief Scientific Officer

Inovio

Roman Yelensky

Chief Technology Officer

Gritstone Oncology

Wigard Kloosterman

Chief Scientific Officer

Frame Therapeutics

Peter Joyce

Chief Executive Officer

Grey Wolf Therapeutics

Michael Ciesielski

Chief Executive Officer

MimiVax

Agnete Fredriksen

Chief Scientific Officer

Vaccibody

Alexandre Reuben

Assistant Professor

The University off Texas MD Anderson Cancer Center

David Reardon

Clinical Director, Center for Neuro- Oncology

Dana-Faber Cancer Institute

Eli Gilboa

Director, Dodson Interdisciplinary Immunotherapy Institute

University of Miami, Miller School of Medicine

Russell Pachynski

Assistant professor, Division of Oncology

Washington University School of Medicine

Mark Findeis

Executive Director, Research Biochemistry

Agenus Bio

Ronit Satchi-Fainaro

Head, Cancer Research and Nanomedicine Laboratory

Tel Aviv University

Alejandro Sepulveda

Scientific Director, Head of Cancer Vaccines

Janssen

Wouter Scheper

Senior Postdoctoral Fellow

Netherlands Cancer Institute

Christopher Rose

Senior Scientist & Group Leader

Genentech

Lena Kranz

Director Cancer Vaccines

BioNTech

Lelia Delamarre

Principal Scientist, Cancer Immunology

Genentech

Hubert Lam

Director Pre-clinical Development

Genocea Biosciences

Helena Florindo

Group Leader, BioNanoSciences – Drug Delivery and Immunotherapy

University of Lisbon

Vipul Bhargava

Principal Scientist

Janssen